Some of the factors driving the growth of the IVD Quality Control Market are rising demand for external quality assurance support, growing number of accredited clinical laboratories and growing adoption of third-party quality controls.
According to research report the In Vitro Diagnostics Quality Control Market is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period.
The prominent players in the In Vitro Diagnostics Quality Control Market are Thermo Fisher Scientific Inc. (US), Technopath Clinical Diagnostics (Ireland), Bio-Rad Laboratories Inc. (US), Randox Laboratories Ltd. (UK), Bio-Techne Corporation (US), Fortress Diagnostics (UK), SeraCare Life Sciences Inc. (US), SERO AS (Norway), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), and Abbott Laboratories Inc. (US).
Recent Developments
> In December 2019, Technopath Clinical Diagnostics (Ireland) and Data Innovations LLC (US) partnered to offer a robust portfolio of quality control data management solutions to their clients.
> In October 2019, Thermo Fisher Scientific (US) launched Acrometrix BCR-ABL Panel, a new external molecular quality control panel for the analytical validation of BCR-ABL test methods.
> In March 2018, Technopath Clinical Diagnostics (Ireland) and Beckman Coulter Inc. (US) entered into a supply and distribution contract wherein Technopath supplied its Multichem QC products and IAMQC data management solutions to Beckman Coulter and allowed it to distribute its QC products in more than 100 countries.
> In February 2018, Qnostics (UK) and Randox Laboratories Ltd. (UK) entered into a partnership wherein Randox Laboratories to sell and distribute Qnostics’ molecular range of products, which strengthened Qnostics’ market penetration.
> In January 2018, Technopath Clinical Diagnostics (Ireland) launched Multichem AMH quality control, a liquid frozen quality control material.
Based on applications, the IVD quality control market is segmented into clinical chemistry, immunochemistry, hematology, microbiology, molecular diagnostics, coagulation & hemostasis and other applications (ESR, urine chemistry, immunology, cardiac assessment, and blood morphology). The molecular diagnostics section is expected to grow at the highest CAGR during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582